- Ongoing, recruitingTherapeutic exploratory (Phase II)
PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARLY BREAST CANCER
This study looks at new ways to treat early breast cancer in women before menopause. It compares a new medicine, giredeastrant, with a common treatment, tamoxifen, to see how they affect cancer cell growth before surgery. It aims to find the best treatment options.
For: ER[+]/HER2[-] & Ki67≥10% early breast cancer (EBC)Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
IBCSG 67-22 PREcoopERA: A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.
This study looks at new ways to treat early breast cancer in women before menopause. It compares different hormone treatments to see which best slows down cancer cell growth, using medicines like giredestrant, triptorelin, and anastrozole. The aim is to find more effective options for this type of breast cancer.
For: ER-positive/HER2-negative early breast cancerSpain · Germany · Italy